# Remeditex Ventures

Remeditex Ventures is a Venture Capital based in Dallas, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Dallas, United States
- **Region:** North America
- **Address:** Dallas, TX, United States
- **Founded:** 2009
- **Assets under management:** Undisclosed
- **Website:** remeditex.com
- **LinkedIn:** https://www.linkedin.com/company/remeditex-ventures

## Regulatory record

- **Reports private funds:** No

## About

Remeditex Ventures translates scientific discovery into the marketplace through business and scientific discipline. The firm develops early-stage biomedical science and aims to make Texas a preferred location for biotechnology companies, venture capitalists, and entrepreneurs. Remeditex Ventures has made 29 investments, including a Series C - II investment in Navitor Pharmaceuticals on January 02, 2019, and has facilitated 7 portfolio exits, including Rodin Therapeutics on November 18, 2019.

## Sectors

- Digital Health
- Healthcare Services
- Enterprise Software

## People

- Dennis Gorman — Managing Director
- Maxim Kholin — Managing Director

## Questions

### Who runs investment decisions at Remeditex Ventures?

Managing Directors Dennis Gorman and Maxim Kholin jointly lead the firm's investment operations. Both were instrumental in architecting the academic-origination model that defines Remeditex's deal flow. The partnership structure is deliberately flat, with the principals directly involved in sourcing, structuring, and board-level governance of portfolio companies.

### How does Remeditex Ventures source proprietary deal flow?

Remeditex derives its pipeline from embedded partnerships with major academic research institutions. Rather than participating in broad auction processes, the firm identifies promising biomedical intellectual property inside university labs, forms a new company around the licensed asset, and leads the initial financing. This origination model gives the firm founder-level equity access and significant influence over clinical and corporate strategy.

### What investment stages does Remeditex Ventures typically target?

The firm operates from the pre-incorporation stage — forming the company around university-originated intellectual property — through Series A and expansion rounds. Its timeline is tied to drug and device development milestones rather than fixed fund-life constraints, allowing Remeditex to support assets through regulatory filing and clinical inflection points.

### How is Remeditex Ventures structurally distinct from a large platform biotech fund?

Most platform biotech funds invest as participants in syndicated Series A and B rounds across dozens of external deals. Remeditex operates further upstream, acting as a company builder and the lead institutional investor in the assets it creates from academic research. This yields a smaller, more concentrated portfolio and a partnership economics structure that differs from a standard 2-and-20 commingled venture fund.

## Related profiles

- [Reliable Fund Management](https://altss.com/profile/reliable-fund-management)
- [Ren Jun Capital](https://altss.com/profile/ren-jun-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/remeditex-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology